Cetuximab - Eli Lilly

Drug Profile

Cetuximab - Eli Lilly

Alternative Names: Anti-EGFR monoclonal antibody 225; C 225; ch 225; Erbitux; IMC-C225; LY-2939777

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California System
  • Developer Array BioPharma; Bristol-Myers Squibb; Centre Jean Perrin; Eli Lilly; Merck KGaA; New York University School of Medicine; Novartis; Pierre Fabre; Roche; University Hospital Ghent; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer
  • Phase III Non-small cell lung cancer
  • Phase II Bladder cancer; Breast cancer; Gastric cancer; Mesothelioma; Rectal cancer
  • Phase Unknown Oesophageal cancer
  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 08 Sep 2017 Efficacy and adverse events data from the phase II PRODIGE 22-ECKINOXE trial in Colorectal cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 08 Sep 2017 Pharmacokinetics, efficacy and adverse events data from a phase I trial in Solid tumours presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 08 Aug 2017 The UK National Institute for Health and Care Excellence (NICE) issues a Final Appraisal Determination (FAD) recommending use of cetuximab in combination with platinum-based chemotherapy as a first-line therapy for Squamous cell carcinoma of the head and neck (SCCHN)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top